The Enforcement Gap: Why Veterinary Medicine Lacks the Legal Guardrails That Protect Human Patients — And What Still Applies

When private equity moves into a new market, it typically finds one of two things: a legal framework that forces compliance, or a legal vacuum that enables extraction. In veterinary medicine, it has found the latter — at least partially. Understanding that gap, what fills it, and what doesn’t is essential context for any veterinarian evaluating corporate partnerships, teleradiology contracts, or the long-term structure of their practice.

The Architecture of Protection in Human Medicine

Human physicians practice inside a dense, overlapping framework of federal laws designed specifically to prevent financial relationships from corrupting clinical judgment. These laws were born from a hard lesson: when doctors are paid to refer patients to facilities in which they have financial interests, patient care suffers and costs rise. Congress and the courts built a system to prevent it.

Three federal statutes form the core of that system.

The Federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b)

Enacted in 1972 and significantly strengthened in 1977 and 1987, the federal Anti-Kickback Statute (AKS) makes it a criminal felony to knowingly and willfully offer, pay, solicit, or receive any remuneration — cash, gifts, free rent, consulting fees, or anything else of value — in exchange for referrals of patients whose care is paid by a federal health program. The statute covers both the payer and the recipient of the kickback. Conviction can result in fines up to $100,000 per violation, imprisonment for up to ten years, and exclusion from Medicare and Medicaid participation. The Department of Justice (DOJ) and the Department of Health and Human Services (HHS) Office of Inspector General (OIG) jointly enforce the statute.

The AKS is deliberately broad. Congress recognized that the forms kickbacks take are limited only by imagination, so the statute sweeps widely. A carefully constructed safe harbor system — developed by the OIG through rulemaking since 1991 — carves out legitimate arrangements: certain employment relationships, personal services contracts at fair market value, properly structured group practice arrangements, and others. But an arrangement that doesn’t fit squarely within a safe harbor isn’t automatically illegal; the test is whether the arrangement has the requisite corrupt intent.

The AKS’s jurisdictional hook is federal health care programs: Medicare, Medicaid, TRICARE, VA benefits, and similar programs. This hook is both the statute’s power and its limit.

The Stark Law (42 U.S.C. § 1395nn)

Named for its primary sponsor, Representative Fortney “Pete” Stark of California, the Physician Self-Referral Law prohibits physicians from referring patients to entities in which the physician or an immediate family member holds a financial interest — for a defined list of “designated health services” payable by Medicare or Medicaid. Unlike the AKS, the Stark Law is a strict liability civil statute: no proof of intent is required. If a financial relationship exists and doesn’t fit within one of more than 30 enumerated exceptions, the referral is prohibited regardless of the physician’s subjective motivation.

The practical significance of Stark is enormous. A physician who owns an interest in an imaging center cannot refer patients to that center for Medicare-covered imaging without fitting within a specific exception. The Centers for Medicare and Medicaid Services (CMS) enforces Stark, and violations result in denial of claims, repayment demands, and civil monetary penalties.

Because Stark violations render associated Medicare claims false, a Stark violation typically generates parallel False Claims Act liability as well.

The False Claims Act (31 U.S.C. § 3729)

Originally enacted during the Civil War to combat defense contractor fraud, the False Claims Act (FCA) imposes liability on anyone who knowingly submits a false or fraudulent claim to the federal government. In the healthcare context, a Medicare or Medicaid claim that resulted from an AKS violation or Stark violation is, by its nature, a false claim. The FCA provides for treble damages — three times the government’s loss — plus civil monetary penalties per false claim.

The FCA’s most powerful mechanism is the qui tam provision, which allows private citizens with inside knowledge of fraud (whistleblowers) to file suit on behalf of the government and collect a portion of any recovery. This creates a self-funding enforcement mechanism that extends far beyond what the DOJ could pursue on its own. Healthcare qui tam cases are among the most productive areas of FCA enforcement, generating billions in annual recoveries.

Why the Federal Framework Stops at the Clinic Door

The reason is simple and structural: every federal healthcare fraud and abuse statute — the AKS, the Stark Law, the FCA in its healthcare application — is anchored to the federal health care programs. Medicare and Medicaid don’t pay veterinary bills. The federal government is not a payer in the veterinary services market. Without that jurisdictional hook, the statutes have no reach.

This is not a gap that was overlooked. It is a gap that was never created in the first place. When Congress designed the AKS and Stark, the concern was protecting federal program integrity and federal taxpayer money. Veterinary care was entirely outside that concern, and nothing has changed legislatively since.

The practical result is that a veterinary hospital system with corporate ownership can structure financial arrangements that would constitute criminal kickbacks in human medicine — paying referral bonuses to general practitioners who steer specialty cases to a corporate-owned specialty hospital, for instance — without triggering federal law. No federal agency has jurisdiction. No DOJ prosecutor has a statute to charge. No OIG exclusion is available. The system of enforcement that would catch such conduct in human medicine simply doesn’t exist for veterinary services.

Where Federal Law Does Reach Veterinary Medicine — And Why It Rarely Does

The statement that federal healthcare fraud law does not apply to veterinary medicine requires an important qualification: it does not apply where the federal government is not paying the bill. Where federal dollars do flow into veterinary services, the jurisdictional hook exists — and with it, the full weight of the AKS, the FCA, and related federal enforcement authority.

That hook is more common in veterinary medicine than most practitioners realize.

Military Working Animals

The United States military maintains thousands of working dogs and horses across all service branches — explosive detection dogs, patrol dogs, search and rescue animals, ceremonial horses. Their veterinary care is funded by the Department of Defense. Military veterinarians are commissioned officers, and veterinary services at military installations are provided under federal contract or directly by federal employees. Where a contractor provides veterinary services to a military installation and a kickback arrangement influences the billing or referral of those services, the AKS and FCA are structurally available. The federal payer connection is direct and unambiguous.

USDA Farm Program and Food Safety Contexts

The U.S. Department of Agriculture (USDA) administers a range of programs that intersect with veterinary services. The National Veterinary Accreditation Program (NVAP) accredits private veterinarians to perform federal functions — issuing health certificates, conducting export inspections, certifying animals for interstate movement. USDA also funds veterinary services through livestock indemnity programs, emergency disease response programs, and the National Animal Health Laboratory Network. Where a veterinarian is being paid through a federal program or contract, or where their certification decisions affect federal benefit payments, the federal nexus required for AKS and FCA applicability may be present.

Federal Research Animal Programs

The National Institutes of Health (NIH), USDA, and other federal agencies fund billions of dollars annually in animal research. Federally funded research institutions must maintain Institutional Animal Care and Use Committees (IACUCs) and comply with the Animal Welfare Act and Public Health Service Policy. Veterinary care for research animals at federally funded institutions is often funded directly through federal grants. A kickback arrangement that influenced the procurement of veterinary services at a federally funded research facility — directing grant dollars toward a vendor based on financial relationships rather than merit — could implicate the FCA’s prohibition on false claims to the federal government.

Other Federal Contexts

The list extends further: U.S. Customs and Border Protection (CBP) working dog programs, the Transportation Security Administration (TSA) explosive detection dog units, the Drug Enforcement Administration (DEA) drug detection dogs, Bureau of Land Management (BLM) wild horse and burro veterinary contracts, and the Federal Emergency Management Agency (FEMA) urban search and rescue canine teams all involve federal dollars funding veterinary services. In each context, the jurisdictional hook that activates federal fraud and abuse law is potentially present.

The Infrastructure Gap

Despite these available legal hooks, federal enforcement in veterinary contexts remains nearly nonexistent — not because the law does not reach it, but because no federal agency has built the institutional infrastructure to pursue it. The HHS OIG, which drives AKS and FCA enforcement in human medicine, has no veterinary mandate. The USDA Office of Inspector General focuses on agricultural program fraud, not veterinary referral arrangements. The DOJ’s healthcare fraud unit is overwhelmed with human medicine cases worth orders of magnitude more in federal dollars.

The result is a significant legal anomaly: federal anti-kickback law theoretically applies wherever federal dollars fund veterinary services, but no enforcement agency is systematically looking for violations. This is not a stable state of affairs as federal veterinary expenditures grow and corporate consolidation increases the financial incentives for improper arrangements.

Rare Enforcement Does Not Mean No Risk: The Consequences Are Real and Can Be Career-Ending

A veterinarian reading this article might reasonably conclude: state anti-kickback laws are rarely enforced against veterinarians, veterinary medical boards (VMBs) rarely pursue financial arrangement cases, and federal enforcement in the veterinary context is nearly nonexistent. That conclusion — while accurate as a description of current enforcement frequency — would be dangerously wrong as a guide to professional conduct.

Rare enforcement is not the same as no enforcement. And in professional licensing, the consequences of being the case that breaks the pattern are not merely inconvenient. They are potentially career-ending, financially devastating, and in some circumstances, criminal.

License Revocation or Suspension

A state VMB that receives a complaint and finds that a veterinarian participated in a referral arrangement that violated the state’s professional ethics rules or anti-kickback statute has full authority to suspend or revoke that veterinarian’s license. License revocation is not a fine. It is the end of the ability to practice. There is no federal floor protecting a licensed veterinarian from state board action, and there is no reliable appeal mechanism that reverses a board finding of serious ethical misconduct. A career built over decades can be ended by a single disciplinary proceeding.

State Criminal Prosecution

In states with anti-kickback statutes that reach veterinary practice — and several do, including California — violations can be prosecuted as criminal offenses. California Business and Professions Code § 650 carries penalties of fines and imprisonment. A veterinarian who participates in a referral arrangement that a state prosecutor characterizes as an illegal kickback scheme faces not just professional consequences but the prospect of a criminal record, fines, and incarceration. The fact that no such prosecution has been widely publicized to date does not mean the exposure does not exist — it means no one has yet decided to make an example.

Federal Criminal and Civil Exposure in Federal Payer Contexts

Veterinarians who provide services where federal dollars are involved — military animals, USDA programs, federally funded research institutions — operate under the full reach of the AKS and the FCA. A violation of the AKS is a federal felony carrying imprisonment of up to ten years and fines up to $100,000 per violation. FCA liability carries treble damages plus per-claim penalties. A veterinarian billing a federal program under an arrangement that involves improper remuneration for referrals faces criminal prosecution, civil liability, and permanent exclusion from federal programs.

Civil Liability Under State Law

A competing veterinary practice that loses referrals to a corporate-owned provider because of an improper financial arrangement has potential claims under state unfair competition law, tortious interference with business relationships, and in some states, private causes of action under the state anti-kickback statute itself. A well-funded plaintiff — such as a competing corporate chain with its own legal department — is not an unlikely adversary. Civil litigation is expensive, reputationally damaging, and time-consuming regardless of outcome.

The Corporate Indemnification Trap

Perhaps the most important — and least understood — risk for employed veterinarians is the disconnect between their employer’s legal exposure and their own. Private equity (PE)-owned veterinary chains that structure financial arrangements involving referral incentives bear the business risk of those arrangements. But the veterinarian who participates holds the professional license that is at stake in any enforcement action.

Many employment contracts at corporate veterinary chains contain indemnification provisions that protect the employer — not the employee — in the event of regulatory action or litigation. A veterinarian who signs such a contract, participates in an arrangement that later draws VMB scrutiny or state prosecution, and then looks to the corporate employer for legal defense and financial support may find themselves without either. The corporation’s attorneys represent the corporation. The individual veterinarian’s license is their own personal asset, and their personal liability is their own personal problem.

This is not hypothetical. It is the documented pattern in analogous human medicine enforcement actions, where individual physicians employed by corporate entities have faced license revocation and criminal prosecution while their corporate employers negotiated settlements that protected the business.

The “I Was Just Following Corporate Policy” Problem

No state VMB, state prosecutor, or federal grand jury will accept “my employer told me to” as a defense to participation in an improper referral arrangement. Professional licenses are issued to individuals. Professional obligations run to individuals. Criminal statutes impose individual liability. A veterinarian who participates in an arrangement because it was presented as standard corporate practice, or because questioning it seemed career-risky, has not thereby insulated themselves from the legal consequences of participation.

The veterinarian’s name is on the license. The veterinarian’s name is on the referral. In any enforcement proceeding, the individual is the respondent — not the PE fund that owns the clinic, not the management company that designed the incentive structure, not the CEO who approved the vendor agreement.

The State Law Patchwork: Partial, Inconsistent, Rarely Enforced

The absence of robust federal law does not mean a complete legal vacuum. Most states have enacted their own anti-kickback statutes or regulations, and some of these reach veterinary practice. But the patchwork is thin, inconsistent, and only sporadically enforced.

State Anti-Kickback Statutes

All fifty states have some version of anti-kickback or anti-referral regulation — the question is whether those laws explicitly cover veterinary practice, and whether they are enforced against it. A 2014 analysis by Frier Levitt, a healthcare law firm, identified that many states had enacted broad business and insurance regulations prohibiting referral arrangements that result in any rebate, refund, commission, discount, or other consideration as compensation for referring clients or customers — language broad enough, on its face, to encompass veterinary referral arrangements. California’s anti-kickback statute (Business and Professions Code § 650), for instance, bars any licensed person from offering or accepting remuneration to refer patients, applies to all payors rather than just government programs, and carries penalties of fines and imprisonment.

However, enforcement against veterinarians under these statutes is rare. State anti-kickback laws were designed and have been administered primarily in the human healthcare context. Regulatory agencies in most states have not developed veterinary-specific guidance, have not pursued veterinary enforcement actions, and have not built institutional knowledge of veterinary referral arrangements. The statutes may be nominally available; the enforcement infrastructure is not.

A vivid illustration of this inconsistency came in the pharmacy context. Between 2013 and approximately 2018, fourteen state pharmacy boards investigated whether veterinary practices that outsourced prescription fulfillment to third-party home delivery services were violating state anti-kickback statutes. Thirteen of the fourteen states ultimately concluded the practice was legal. One — Nevada — pursued enforcement and was handed a significant defeat in state and federal court. The episode illustrates both that state anti-kickback laws can reach veterinary arrangements and that the outcomes are highly unpredictable.

State Veterinary Medical Board Discipline

All fifty states license veterinarians through state VMBs, which have authority to discipline licensees for conduct that violates professional ethics or the state veterinary practice act. In practice, VMBs focus predominantly on clinical competence issues — negligent treatment, controlled substance violations, record-keeping failures. The boards generally lack the investigative capacity, the legal expertise, and the institutional mandate to pursue complex financial arrangement cases. No significant VMB disciplinary actions against veterinarians for kickback-type conduct have been widely reported.

Common Law and Contract Remedies

Where statutory law is absent or unenforced, aggrieved parties occasionally turn to common law theories. Breach of fiduciary duty, tortious interference, and unfair competition claims have been used in analogous commercial contexts. These remedies are available in theory but are expensive to pursue, require demonstrated concrete harm, and are typically accessible only to commercial parties — not to individual pet owners or referring veterinarians who suspect that a corporate arrangement is compromising the independence of specialist recommendations.

The Enforcement Landscape at a Glance

The following table summarizes the key enforcement mechanisms available in human medicine, and their applicability — or inapplicability — to veterinary services.

Where Federal Enforcement Does Apply: The Federal Trade Commission’s Antitrust Jurisdiction

There is one area of federal law where veterinary medicine is treated identically to human medicine: antitrust enforcement. The Federal Trade Commission (FTC) has jurisdiction over unfair methods of competition in or affecting commerce, without restriction to any particular industry. Veterinary services are commerce. Veterinary clinic acquisitions that substantially lessen competition violate Section 7 of the Clayton Act whether the clinics treat humans or animals. The FTC’s authority here is full and unambiguous.

This is a fundamentally different type of protection than anti-kickback law. Antitrust law doesn’t police whether a financial relationship has corrupted an individual doctor’s referral decisions. It polices whether a company’s accumulation of market power has eliminated competition itself — whether pet owners in a given market have been left with fewer choices, higher prices, and reduced quality because a private equity firm has bought up all of the competing specialty practices.

Case Study: The FTC’s Hammer Drops on JAB Consumer Partners

In 2022, the Federal Trade Commission issued two enforcement actions against JAB Consumer Partners — a Luxembourg-based private equity (PE) firm — in a span of less than two months. Together, they represent the clearest demonstration to date that the FTC’s antitrust authority is a real and consequential check on consolidation in veterinary services, even in the absence of any healthcare-specific federal enforcement framework.

JAB is one of the largest consumer-focused PE firms in the world, with investments spanning coffee (Keurig, JDE Peets, Panera), beauty (Coty), and food services. In veterinary medicine, JAB had assembled a substantial and growing platform through two chains: Compassion-First Pet Hospitals and National Veterinary Associates (NVA), which it had combined into a single entity. That prior acquisition had itself drawn FTC scrutiny, resulting in an earlier consent order in 2020.

Action One: JAB / SAGE Veterinary Partners ($1.1 Billion)

In June 2022, JAB announced a proposed $1.1 billion acquisition of SAGE Veterinary Partners, a California-focused operator of specialty and emergency veterinary clinics. The FTC issued its complaint and proposed consent order in June 2022, with the final order issued August 5, 2022.

The FTC alleged that the acquisition would substantially lessen competition in three defined geographic markets: the greater Austin, Texas area; the greater San Francisco, California area; and the Oakland-Berkeley-Concord, California corridor. In each market, the FTC found that Compassion-First/NVA and SAGE were close, head-to-head competitors for specialty and emergency veterinary services — and that a merger would eliminate that competition, increasing the likelihood that the combined entity would raise prices or reduce service quality.

The final consent order required JAB to divest six SAGE clinics to United Veterinary Care (UVC) as a condition of completing the acquisition. The order also imposed prospective prior notice and prior approval requirements on JAB’s future acquisitions — a structural remedy designed to ensure that JAB could not simply re-aggregate the divested assets through subsequent smaller deals.

Action Two: JAB / Ethos Veterinary Health ($1.65 Billion)

The Ethos action was larger in deal size and geographic scope. JAB’s proposed $1.65 billion acquisition of VIPW, LLC — the parent company of Ethos Veterinary Health — would have added Ethos’s specialty and emergency clinics, operating in nine states, to JAB’s Compassion-First/NVA platform.

The FTC complaint, issued June 28, 2022, identified four geographic markets where the combination would produce anticompetitive effects. In one market — the Richmond, Virginia area for veterinary oncology services — the FTC alleged the acquisition would produce a merger to monopoly. In three additional markets (the Washington, D.C. metro area, the Denver, Colorado metro area, and the San Francisco, California area) the FTC alleged the acquisition would eliminate close head-to-head competition.

“For the second time in a month, the FTC is taking action to prevent private equity firm JAB from gobbling up competitors in regional markets that are already concentrated.” — Holly Vedova, FTC Bureau of Competition Director, June 2022

The final consent order, approved unanimously 5-0 by the Commission and finalized in October 2022, required five clinic divestitures. Three clinics — The Oncology Service-Richmond, The Oncology Service-Springfield, and The Oncology Service-Leesburg — were sold to UVC. Two clinics — Wheat Ridge Animal Hospital in Denver and Pet Emergency + Specialty Center of Marin near San Francisco — were sold to Veritas Veterinary Partners.

As with the SAGE order, the Ethos consent order imposed prospective prior approval requirements, requiring JAB to obtain FTC approval before acquiring any specialty or emergency veterinary clinic within 25 miles of an existing JAB-owned clinic anywhere in California, Colorado, the District of Columbia, Virginia, or Maryland. It also imposed a 30-day prior notice requirement for acquisitions nationwide, and the FTC appointed a monitor to oversee compliance.

What the JAB Actions Established

The two 2022 JAB enforcement actions established several important precedents. First, they confirmed that the FTC will define veterinary services markets with geographic precision — specific metro areas where local competition between specific providers was being eliminated, not broad national markets. Second, they established that PE rollup strategies in veterinary services are subject to the same antitrust scrutiny as rollups in any other market. Third, the prospective prior approval provisions established that the FTC can impose ongoing oversight of a company’s entire acquisition strategy going forward. Fourth, the 5-0 unanimous votes in both actions signaled broad bipartisan consensus that veterinary services consolidation warrants serious antitrust scrutiny.

The Limits of Antitrust as a Substitute

The JAB enforcement actions are consequential and important. But antitrust law, however vigorously enforced, cannot do what anti-kickback law does. Antitrust law intervenes at the structural level: it prevents one company from accumulating so much market power that competition itself is destroyed. It operates primarily through merger review and through structural remedies like divestitures. What it does not do is police the ongoing conduct of market participants at the level of individual clinical decisions.

Anti-kickback law, by contrast, operates at the transaction level. It is concerned with whether the specific clinical decision to refer a patient to a specific provider was made on the basis of clinical merit, or was corrupted by a financial relationship. A practice that refers all of its radiology cases to a teleradiology company in which it holds equity, or which pays its radiologists above-market fees in exchange for directing general practice referrals to its specialty affiliate, may not have violated antitrust law — it hasn’t necessarily reduced competition in its market. But if it were in human medicine, it would have violated the AKS and Stark Law.

In veterinary medicine, that conduct is unregulated at the federal level. A corporate veterinary chain can create internal referral arrangements, software integrations, or financial incentive structures that direct specialty work to affiliated providers — without any federal legal prohibition. The FTC can stop the chain from becoming the only specialty provider in a given city. It cannot stop the chain from structuring incentives that steer cases away from independent competitors once multiple providers remain in the market.

This is where the profession’s greatest vulnerability lies. Horizontal consolidation — buying up competitors — is the behavior antitrust law targets. Vertical integration — controlling the referral pathway through software, financial relationships, and institutional incentives — is the behavior anti-kickback law targets. In veterinary medicine, only the former is robustly addressed.

What Professional Regulation and Ethics Require — and Don’t Provide

The American Veterinary Medical Association’s Principles of Veterinary Medical Ethics state clearly that veterinarians should base referral decisions on the best interests of patients and clients, not on financial self-interest or business relationships. These principles have the force of professional ethics within the profession. They do not have the force of law, and violating them carries no federal penalty.

State VMBs can, in theory, discipline veterinarians who violate these principles. But the institutional reality is that VMBs are complaint-driven bodies focused on clear-cut misconduct cases. A veterinarian who refers 90% of imaging cases to a teleradiology company in which their corporate employer holds equity is unlikely to face a VMB complaint, because the pet owner has no way to know the referral was influenced by financial interest — and the referring veterinarian may not even be aware of the corporate relationship.

The opacity of corporate ownership structures in veterinary medicine compounds this problem significantly. As PE platforms acquire independent practices and absorb them into consolidated entities, the financial relationships that might influence clinical decisions become invisible at the point of care. A pet owner in a JAB-affiliated clinic interacts with a veterinarian, not with JAB. They have no visibility into whether the specialist their veterinarian recommends is recommended because that specialist is the best choice for their pet, or because that specialist is part of the same corporate family.

The FTC’s prior approval requirements address this at the macro level. But they don’t address what happens when a corporate chain owns two specialists and an independent practice refers to both — and one of them happens to pay the general practitioner’s platform a technology fee, integrates seamlessly with the platform’s Picture Archiving and Communication System (PACS), or participates in a preferred vendor arrangement.

Looking Forward: Closing the Gap

The enforcement gap in veterinary medicine is not inevitable. It reflects the historical fact that veterinary services were not included in the federal healthcare regulatory framework — not that they cannot be. Several avenues exist for closing or narrowing the gap.

State legislative action is the most immediately actionable path. Several states have already enacted broad anti-kickback statutes that reach veterinary practice by their terms. Others could do so deliberately, extending existing healthcare anti-kickback provisions to explicitly cover veterinary referral arrangements. The California model — applying the prohibition to all payors, not just government programs — is the appropriate template, because it does not require a federal program connection to apply.

Federal legislative action is a longer-term prospect. A free-standing federal veterinary anti-kickback statute, modeled on the existing AKS but shorn of its federal program jurisdictional requirement, could establish a national standard. The Save Our Pets Act and similar legislative proposals addressing corporate veterinary consolidation have introduced the concept of federal veterinary-specific regulation into the Congressional conversation.

FTC enforcement of Section 5’s unfair methods of competition authority remains the most immediate available federal tool beyond merger review. Section 5 has historically been interpreted to reach conduct beyond what Section 1 and Section 2 of the Sherman Act prohibit — including, in some circumstances, conduct that is merely unfair rather than strictly anticompetitive in a technical sense. Whether the FTC will deploy Section 5 against specific veterinary referral arrangements that fall short of monopolization is an open question.

Transparency requirements represent a lower-friction intervention. Requiring corporate veterinary entities to disclose financial relationships to pet owners at the point of referral would not prevent incentivized referrals but would enable informed pet owners to seek independent second opinions and would create market pressure against obvious conflicts.

Conclusion: What the Profession Needs to Ask

The legal framework that governs veterinary medicine’s commercial relationships is not designed for the market that now exists. It was built for a profession of independent practitioners in small practices — not for a market where PE platforms own hundreds of clinics, employ thousands of veterinarians as salaried workers, and control specialist referral pathways through software integrations, vendor agreements, and corporate financial structures.

The FTC’s actions against JAB Consumer Partners in 2022 demonstrated that federal antitrust enforcement is available and willing to protect competition in veterinary markets. That is significant and should not be minimized. But antitrust law is a blunt structural instrument — it prevents monopoly, not the subtler corruption of clinical judgment that anti-kickback law is designed to address.

The questions the profession should be asking are not difficult to identify. When a corporate-owned general practice recommends a specific specialist, does the recommendation reflect the best available care for that patient? When a teleradiology platform integrates seamlessly with a practice management system, is that integration priced at fair market value — or is it below-market, with the deficit made up in directed referral flow? When a corporate entity installs preferred vendor relationships or internal routing rules in its software, does that routing reflect clinical evidence — or financial architecture?

In human medicine, these questions have imperfect but real legal answers. In veterinary medicine, they do not. The profession, the regulators who oversee it, and the pet owners who depend on it would benefit from honest acknowledgment of that gap — and from a serious conversation about how to close it.

The FTC’s hammer has fallen twice on JAB Consumer Partners. It cannot fall on arrangements that antitrust law was never designed to reach.